Joseph P. Hagan's most recent trade in Regulus Therapeutics Inc was a trade of 1,350,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 1,350,000 | 1,350,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 30 Jan 2025 | 50,000 | 260,808 (1%) | 0% | 1.1 | 54,260 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 115,290 | 222,572 (1%) | 0% | 1.3 | 145,634 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 11,764 | 210,808 (1%) | 0% | 1.3 | 14,860 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 990,000 | 990,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Hagan Joseph P. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.19 per share. | 18 Jan 2024 | 14,580 | 57,112 (0%) | 0% | 1.2 | 17,359 | Common Stock |
| Regulus Therapeutics Inc | Joseph Hagan P. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 249,000 | 249,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Joseph Hagan P. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 30,000 | 71,692 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 1,312,500 | 1,312,500 | - | - | Stock Option (Right to Buy) | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 12,233 (0%) | 0% | - | Common Stock | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 10.58 per share. | 18 May 2023 | 272 | 11,961 (0%) | 0% | 10.6 | 2,878 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2022 | 1,600,000 | 1,600,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.22 per share. | 12 Jan 2022 | 100,000 | 417,006 (1%) | 0% | 0.2 | 21,520 | Common Stock |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 40,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.08 per share. | 03 Jan 2022 | 40,000 | 43,500 (0%) | 0% | 5.1 | 203,200 | Common Stock |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 22.58 per share. | 03 Jan 2022 | 39,366 | 4,134 (0%) | 0% | 22.6 | 888,884 | Common Stock |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 23.29 per share. | 03 Jan 2022 | 634 | 3,500 (0%) | 0% | 23.3 | 14,766 | Common Stock |
| Aurinia Pharmaceuticals Inc | Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 17 May 2021 | 4,186 | 316,292 (1%) | 0% | 0.9 | 3,726 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | 14 Apr 2021 | 75,850 | 320,478 (1%) | 0% | - | Common Stock | ||
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | 14 Apr 2021 | 7,585 | 0 | - | - | Class A-2 Convertible Preferred Stock | ||
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 16 Feb 2021 | 4,144 | 244,628 (1%) | 0% | 1.7 | 7,128 | Common Stock |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Joseph P. Hagan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.60 per share. | 14 Aug 2020 | 4,245 | 222,088 (1%) | 0% | 0.6 | 2,568 | Common Stock |